$3.99
0.235.98%
At Close: -
$3.99
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Sutro Biopharma
STRONASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Sutro Biopharma (NASDAQ:STRO) Stock, Analyst Ratings, Price Targets, Forecasts
Sutro Biopharma Inc has a consensus price target of $14.44 based on the ratings of 9 analysts. The high is $30 issued by Berenberg on November 17, 2021. The low is $8 issued by Wedbush on May 14, 2024. The 3 most-recent analyst ratings were released by Oppenheimer, HC Wainwright & Co., and Wedbush on May 15, 2024, May 14, 2024, and May 14, 2024, respectively. With an average price target of $10 between Oppenheimer, HC Wainwright & Co., and Wedbush, there's an implied 150.63% upside for Sutro Biopharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
HC Wainwright & Co.
Wedbush
B of A Securities
JMP Securities
1calculated from analyst ratings
Analyst Ratings for Sutro Biopharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/15/2024 | Buy Now | 150.63% | Oppenheimer | Jay Olson | $10 → $10 | Maintains | Outperform | Get Alert |
| 05/14/2024 | Buy Now | 200.75% | HC Wainwright & Co. | Andrew Fein | → $12 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 100.5% | Wedbush | David Nierengarten | → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 05/08/2024 | Buy Now | 200.75% | B of A Securities | Tazeen Ahmad | → $12 | Initiates | → Buy | Get Alert |
| 04/03/2024 | Buy Now | 326.07% | JMP Securities | Reni Benjamin | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 04/03/2024 | Buy Now | 175.69% | Piper Sandler | Edward Tenthoff | $12 → $11 | Reiterates | Overweight → Overweight | Get Alert |
| 04/03/2024 | Buy Now | 150.63% | Oppenheimer | Jay Olson | $10 → $10 | Maintains | Outperform | Get Alert |
| 04/03/2024 | Buy Now | 351.13% | Truist Securities | Asthika Goonewardene | $25 → $18 | Maintains | Buy | Get Alert |
| 03/28/2024 | Buy Now | 150.63% | Oppenheimer | Jay Olson | → $10 | Maintains | Outperform | Get Alert |
| 03/27/2024 | Buy Now | 150.63% | Oppenheimer | Jay Olson | $10 → $10 | Maintains | Outperform | Get Alert |
| 03/26/2024 | Buy Now | 326.07% | JMP Securities | Reni Benjamin | — | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/26/2024 | Buy Now | 100.5% | Wedbush | David Nierengarten | $12 → $8 | Maintains | Outperform | Get Alert |
| 03/26/2024 | Buy Now | 200.75% | HC Wainwright & Co. | Andrew Fein | → $16 | Maintains | Buy | Get Alert |
| 11/15/2023 | Buy Now | 200.75% | Piper Sandler | Edward Tenthoff | $18 → $12 | Maintains | Overweight | Get Alert |
| 11/14/2023 | Buy Now | 301% | HC Wainwright & Co. | Andrew Fein | → $16 | Reiterates | Buy → Buy | Get Alert |
| 11/09/2023 | Buy Now | 200.75% | Deutsche Bank | James Shin | → $12 | Initiates | → Buy | Get Alert |
| 10/23/2023 | Buy Now | 200.75% | Wedbush | David Nierengarten | → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 10/06/2023 | Buy Now | 150.63% | Oppenheimer | Jay Olson | → $10 | Initiates | → Outperform | Get Alert |
| 09/06/2023 | Buy Now | 526.57% | Truist Securities | Asthika Goonewardene | → $25 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2023 | Buy Now | 326.07% | JMP Securities | Reni Benjamin | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/11/2023 | Buy Now | 301% | HC Wainwright & Co. | Andrew Fein | → $16 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | 200.75% | Wedbush | David Nierengarten | $20 → $12 | Maintains | Outperform | Get Alert |
| 06/27/2023 | Buy Now | 326.07% | JMP Securities | Reni Benjamin | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/12/2023 | Buy Now | 326.07% | JMP Securities | Reni Benjamin | → $17 | Reiterates | → Market Outperform | Get Alert |
| 05/17/2023 | Buy Now | 326.07% | JMP Securities | Reni Benjamin | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/16/2023 | Buy Now | 301% | HC Wainwright & Co. | Andrew Fein | → $16 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2023 | Buy Now | 326.07% | JMP Securities | Reni Benjamin | $20 → $17 | Maintains | Outperform | Get Alert |
| 03/31/2023 | Buy Now | 401.25% | Wedbush | David Nierengarten | → $20 | Reiterates | → Outperform | Get Alert |
| 03/31/2023 | Buy Now | 301% | HC Wainwright & Co. | Andrew Fein | $20 → $16 | Maintains | Buy | Get Alert |
| 01/13/2023 | Buy Now | 526.57% | Truist Securities | Asthika Goonewardene | $21 → $25 | Maintains | Buy | Get Alert |
| 01/10/2023 | Buy Now | 351.13% | Piper Sandler | Edward Tenthoff | $16 → $18 | Maintains | Overweight | Get Alert |
| 11/09/2022 | Buy Now | 401.25% | HC Wainwright & Co. | Andrew Fein | $30 → $20 | Maintains | Buy | Get Alert |
| 08/23/2022 | Buy Now | 426.32% | Truist Securities | Asthika Goonewardene | $37 → $21 | Maintains | Buy | Get Alert |
| 05/23/2022 | Buy Now | 250.88% | Piper Sandler | Edward Tenthoff | $29 → $14 | Maintains | Overweight | Get Alert |
| 05/11/2022 | Buy Now | 651.88% | HC Wainwright & Co. | Andrew Fein | $35 → $30 | Maintains | Buy | Get Alert |
| 11/17/2021 | Buy Now | 651.88% | Berenberg | Zhiqiang Shu | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Sutro Biopharma (STRO) stock?
The latest price target for Sutro Biopharma (NASDAQ:STRO) was reported by Oppenheimer on May 15, 2024. The analyst firm set a price target for $10.00 expecting STRO to rise to within 12 months (a possible 150.63% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sutro Biopharma (STRO)?
The latest analyst rating for Sutro Biopharma (NASDAQ:STRO) was provided by Oppenheimer, and Sutro Biopharma maintained their outperform rating.
When was the last upgrade for Sutro Biopharma (STRO)?
There is no last upgrade for Sutro Biopharma
When was the last downgrade for Sutro Biopharma (STRO)?
There is no last downgrade for Sutro Biopharma.
When is the next analyst rating going to be posted or updated for Sutro Biopharma (STRO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sutro Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sutro Biopharma was filed on May 15, 2024 so you should expect the next rating to be made available sometime around May 15, 2025.
Is the Analyst Rating Sutro Biopharma (STRO) correct?
While ratings are subjective and will change, the latest Sutro Biopharma (STRO) rating was a maintained with a price target of $10.00 to $10.00. The current price Sutro Biopharma (STRO) is trading at is $3.99, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.